MX2024007456A - Manabodies dirigidos a antígenos tumorales p53 y métodos de uso. - Google Patents

Manabodies dirigidos a antígenos tumorales p53 y métodos de uso.

Info

Publication number
MX2024007456A
MX2024007456A MX2024007456A MX2024007456A MX2024007456A MX 2024007456 A MX2024007456 A MX 2024007456A MX 2024007456 A MX2024007456 A MX 2024007456A MX 2024007456 A MX2024007456 A MX 2024007456A MX 2024007456 A MX2024007456 A MX 2024007456A
Authority
MX
Mexico
Prior art keywords
methods
manabodies
targeting
tumor antigens
mammal
Prior art date
Application number
MX2024007456A
Other languages
English (en)
Spanish (es)
Inventor
Shibin Zhou
Bert Vogelstein
Kenneth W Kinzler
Nickolas Papadopoulos
Sarah Dinapoli
Emily Han-Chung Hsiue
Brian J Mog
Katharine M Wright
Sandra B Gabelli
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2024007456A publication Critical patent/MX2024007456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2024007456A 2021-12-16 2022-12-15 Manabodies dirigidos a antígenos tumorales p53 y métodos de uso. MX2024007456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163290353P 2021-12-16 2021-12-16
PCT/US2022/053065 WO2023114430A1 (en) 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using

Publications (1)

Publication Number Publication Date
MX2024007456A true MX2024007456A (es) 2024-09-10

Family

ID=86773477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007456A MX2024007456A (es) 2021-12-16 2022-12-15 Manabodies dirigidos a antígenos tumorales p53 y métodos de uso.

Country Status (10)

Country Link
US (1) US20250034252A1 (https=)
EP (1) EP4448583A4 (https=)
JP (1) JP2024546923A (https=)
KR (1) KR20240127981A (https=)
CN (1) CN118541396A (https=)
AU (1) AU2022415459A1 (https=)
CA (1) CA3242393A1 (https=)
IL (1) IL313491A (https=)
MX (1) MX2024007456A (https=)
WO (1) WO2023114430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106598A1 (en) * 2023-11-13 2025-05-22 Clasp Therapeutics, Inc. Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

Also Published As

Publication number Publication date
CN118541396A (zh) 2024-08-23
IL313491A (en) 2024-08-01
JP2024546923A (ja) 2024-12-26
CA3242393A1 (en) 2023-06-22
WO2023114430A1 (en) 2023-06-22
EP4448583A4 (en) 2025-12-17
KR20240127981A (ko) 2024-08-23
AU2022415459A1 (en) 2024-07-04
US20250034252A1 (en) 2025-01-30
EP4448583A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
EP4644427A3 (en) Manabodies and methods of using
BR112021016955A2 (pt) Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2022006230A (es) Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
EA202190088A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
PE20250740A1 (es) Anticuerpos multiespecificos con especificidad para ror1 y cd3
MX2021012767A (es) Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
PE20231573A1 (es) Anticuerpos biespecificos cd47-cd38
WO2022174103A3 (en) Monoclonal antibodies specific for human ror1
MX2024007456A (es) Manabodies dirigidos a antígenos tumorales p53 y métodos de uso.
ZA202308896B (en) Antibodies binding trop2 and uses thereof
MX2023014527A (es) Terapias de combinacion para el tratamiento del cancer
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
WO2023225528A3 (en) Anti-cd84 antibodies and uses thereof
BR112021020873A2 (pt) Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3
MX2025004751A (es) Anticuerpos anti molecula de adhesion celular l1 (l1-cam) y sus usos para aplicaciones diagnosticas y terapeuticas
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
WO2022082030A3 (en) Antigen-binding proteins and related methods of use
MX2024014019A (es) Métodos para el tratamiento del cáncer de próstata resistente a la castración metastásico con anticuerpos biespecíficos anti-psma x anti-anticuerpos de cd3 solos o en combinación con anticuerpos anti-pd-1
WO2010004438A3 (en) Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
WO2022026807A3 (en) Antibodies targeting sars-cov-2 and uses thereof
WO2021154978A3 (en) Human blood-brain barrier targeting antibodies